ImmunoGen Signs Partnership with Vertex for Conditioning Agents worth US$352 M

By Swati Sharan

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 28 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2774     ISSN: 1756-7874

Section: Licensing



In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a global multi-target license and option agreement with ImmunoGen to leverage the latter’s antibody-drug conjugate (ADC) technology to discover targeted conditioning agents for use with gene editing...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details